Stay updated on Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision history now shows an addition of Revision: v3.3.2 and removal of Revision: v3.2.0.SummaryDifference0.0%

- Check16 days agoChange DetectedThe page removed a government funding notice, which is a minor administrative change and does not affect the study record or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check38 days agoChange DetectedA new version entry was added to the Record History, showing an updated submission date. No core study data appear to be altered.SummaryDifference0.0%

- Check60 days agoChange Detected- Added a government-operation notice and status links, clarifying potential delays and current NIH Clinical Center openness. - Removed the previous version tag (v3.1.0) and introduced v3.2.0.SummaryDifference7%

- Check68 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.2%

- Check83 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2; 'Back to Top' removed—a minor UI cleanup with no substantive content changes.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.